Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524334 | 1.00 | MEN1 (0.43) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL9652607 | 0.93 | MEN1 (0.44) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL5063668 | 0.91 | MEN1 (0.37) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL25396096 | 0.87 | KMT2A (0.34) | MEN1KMT2ATSHRALDH1A1LCK | |
| SCHEMBL152625 | 0.86 | TSHR (0.43) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL27497447 | 0.84 | TSHR (0.42) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL24726035 | 0.84 | TSHR (0.37) | MEN1KMT2ATSHR | |
| SCHEMBL5063666 | 0.83 | MEN1 (0.32) | MEN1KMT2ATSHR | |
| SCHEMBL27895185 | 0.82 | TSHR (0.40) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL7933127 | 0.82 | MEN1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119782-A1 | METHOD FOR THE MANUFACTURE OF NEW AMINE | EVONIK OPERATIONS GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| EP-4298104-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | Agilent Technologies, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022183081-A9 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2022183081-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220275019-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. | 2022-09-01 | — | — | US | claimed |
| CN-103370416-A | Modified single-strand polynucleotide | DAIICHI SANKYO CO LTD | 2013-10-23 | — | — | CN | claimed |
| WO-2025119782-A1 | METHOD FOR THE MANUFACTURE OF NEW AMINE | EVONIK OPERATIONS GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| EP-4298104-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | Agilent Technologies, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022183081-A9 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022183081-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| US-20220275019-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. | 2022-09-01 | — | — | US | disclosed |
| EP-3952917-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952916-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-0367040-B1 | COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE | Kabi Pharmacia AB (SE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0202758-B1 | HYBRIDIZATION METHOD AND PROBES THEREFOR | Zeneca Limited (GB) | 1991-09-25 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0367040-A1 | Compounds for the treatment of urinary incontinence | Kabi Pharmacia AB (SE) | 1990-05-09 | — | — | EP | disclosed |
| EP-0305201-A2 | Protected biotin derivatives | ZENECA LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
| EP-0202758-A1 | Hybridization method and probes therefor | ZENECA LIMITED (GB) | 1986-11-26 | — | — | EP | disclosed |
| US-4038210-A | BETA-AMINO NITRILE CATALYSTS FOR POLYURETHANE PREPARATION | UNION CARBIDE CORPORATION (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275019-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | NSUN2, RNASEH1, RNMT | MEN1 1215/4885KMT2A 625/4885TSHR 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.